Information:
Fel:
ID
34383
Beskrivning
Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00806481
Länk
https://clinicaltrials.gov/show/NCT00806481
Nyckelord
Versioner (1)
- 2019-01-17 2019-01-17 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
17 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Kidney Failure, Chronic NCT00806481
Eligibility Kidney Failure, Chronic NCT00806481
- StudyEvent: Eligibility
Similar models
Eligibility Kidney Failure, Chronic NCT00806481
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
chronic kidney disease patients aged 18 to 80 years
boolean
ID.2
Item
chronic kidney disease stage 3 (defined as a glomerular filtration rate of 30-60 ml/min/1.73m2)
boolean
ID.3
Item
office blood pressure controlled to less than 140/90 mmhg for 12 months before entry into the study
boolean
ID.4
Item
total cholesterol less than 5.5 mmol/l
boolean
ID.5
Item
existing or previous treatment within 1 year with a phosphate binder or vitamin d analogue
boolean
ID.6
Item
uncontrolled hyperphosphataemia (serum phosphate >1.8 mmol/l)
boolean
ID.7
Item
uncontrolled secondary hyperparathyroidism (pth >80 pg/ml)
boolean
ID.8
Item
diabetes mellitus
boolean
ID.9
Item
pregnancy
boolean
ID.10
Item
moderate-severe cardiac valvular disease
boolean